Signal MD Anderson phase 1 trial reported disease stabilization in pancreatic cancer

Summary

The chapter's clinical case is a phase 1 trial at the University of Texas MD Anderson Cancer Center in which pancreatic cancer patients with no remaining options showed disease stabilization after engineered exosomes targeted a mutation that had defeated previous drugs, which the chapter presents as one of several early studies.